Metformin, hepatitis C, and insulin resistance: Sufficient evidence?

Hepatology

Volumn 50, Issue 6, 2009, Pages 2054-2055

  Yilmaz, Yusuf ^a   Yonal, Oya ^a   Imeryuz, Nese ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PEGINTERFERON; RIBAVIRIN;

CLINICAL TRIAL; DRUG SAFETY; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; NORMAL VALUE; PRIORITY JOURNAL; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERFERON ALFA-2A; MALE; METFORMIN; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 73149098146     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23359     Document Type: Letter

References (4)

1. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, et al. Treatment of insulin resistance with met-formin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. HEPATOLOGY 2009; doi:10.1002/ hep.23206
2. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, et al. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in non-diabetic patients with chronic hepatitis C: a multicentre study. Aliment Pharmacol Ther 2009; doi:10.1111/j.1365-2036.2009. 04094.x
3. Cook DI, Gebski VJ, Keech AC. Subgroup analysis in clinical trials. Med J Aust 2004;180:289-291.
4. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting. Stat Med 2000;21:2917-2930.